PT  - JOURNAL ARTICLE
AU  - Soyon Hong
AU  - Omar Quintero-Monzon
AU  - Beth L. Ostaszewski
AU  - Daniel R. Podlisny
AU  - William T. Cavanaugh
AU  - Ting Yang
AU  - David M. Holtzman
AU  - John R. Cirrito
AU  - Dennis J. Selkoe
TI  - Dynamic Analysis of Amyloid β-Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal Aβ during Age-Related Plaque Formation
AID  - 10.1523/JNEUROSCI.3272-11.2011
DP  - 2011 Nov 02
TA  - The Journal of Neuroscience
PG  - 15861--15869
VI  - 31
IP  - 44
4099  - http://www.jneurosci.org/content/31/44/15861.short
4100  - http://www.jneurosci.org/content/31/44/15861.full
SO  - J. Neurosci.2011 Nov 02; 31
AB  - Growing evidence supports the hypothesis that soluble, diffusible forms of the amyloid β-peptide (Aβ) are pathogenically important in Alzheimer's disease (AD) and thus have both diagnostic and therapeutic salience. To learn more about the dynamics of soluble Aβ economy in vivo, we used microdialysis to sample the brain interstitial fluid (ISF), which contains the most soluble Aβ species in brain at steady state, in >40 wake, behaving APP transgenic mice before and during the process of Aβ plaque formation (age 3–28 months). Diffusible forms of Aβ, especially Aβ42, declined significantly in ISF as mice underwent progressive parenchymal deposition of Aβ. Moreover, radiolabeled Aβ administered at physiological concentrations into ISF revealed a striking difference in the fate of soluble Aβ in plaque-rich (vs plaque-free) mice: it clears more rapidly from the ISF and becomes more associated with the TBS-extractable pool, suggesting that cerebral amyloid deposits can rapidly sequester soluble Aβ from the ISF. Likewise, acute γ-secretase inhibition in plaque-free mice showed a marked decline of Aβ38, Aβ40, and Aβ42, whereas in plaque-rich mice, Aβ42 declined significantly less. These results suggest that most of the Aβ42 that populates the ISF in plaque-rich mice is derived not from new Aβ biosynthesis but rather from the large reservoir of less soluble Aβ42 in brain parenchyma. Together, these and other findings herein illuminate the in vivo dynamics of soluble Aβ during the development of AD-type neuropathology and after γ-secretase inhibition and help explain the apparent paradox that CSF Aβ42 levels fall as humans develop AD.